Loading...
Loading...
Size: 5mg
Triple-Action Metabolic Compound
In stock · Ships same day · Free shipping over $150
Technical specifications
Molecular Profile
First-in-class triple incretin (GLP-1 / GIP / glucagon) receptor agonist.
Storage Requirements
Lyophilized (powder)
-20°C · stable long-term
Reconstituted / in solution
2-8°C · use within 30 days
Retatrutide (LY3437943) is a first-in-class triple incretin receptor agonist that simultaneously engages GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors through a single 39-amino acid peptide chain with a C20 fatty diacid modification for albumin binding and extended pharmacokinetics. This triple mechanism is unique in metabolic peptide research: GLP-1 receptor activation suppresses appetite and stimulates glucose-dependent insulin secretion; GIP receptor engagement potentiates insulin response and may improve beta-cell function; and glucagon receptor activation increases hepatic fatty acid oxidation, energy expenditure, and thermogenesis. Phase 2 clinical data published in the New England Journal of Medicine reported unprecedented body weight reductions of up to 24.2% at 48 weeks with the highest dose, exceeding results observed with both semaglutide (GLP-1 only) and tirzepatide (dual GIP/GLP-1). The glucagon receptor component provides the mechanistic addition absent from dual agonists, driving increased energy expenditure rather than relying solely on caloric intake reduction. Retatrutide is currently in Phase 3 clinical trials for metabolic indications. This is a research-grade compound for laboratory investigation, not an FDA-approved product.
Simultaneously engages GLP-1, GIP, and glucagon receptors in a single molecule — the only triple agonist in advanced clinical development. Phase 2 data demonstrated that this three-receptor approach produced body weight reductions of up to 24.2% at 48 weeks, surpassing results achieved by single and dual agonists in comparable timeframes.
Glucagon receptor activation increases basal metabolic rate through hepatic fatty acid oxidation and thermogenesis, directly increasing caloric expenditure rather than relying solely on appetite suppression. This energy expenditure component is the mechanistic advantage that distinguishes retatrutide from dual GIP/GLP-1 agonists like tirzepatide.
Engages both GLP-1 and GIP receptor-mediated satiety pathways simultaneously, providing redundant appetite suppression through multiple hypothalamic and brainstem signaling cascades. Clinical research subjects reported significant reductions in hunger scores and caloric intake, consistent with the combined incretin receptor activation profile.
Published research protocols reference weekly subcutaneous administration. Store refrigerated at 2-8°C.
Every batch is independently analyzed by a third-party laboratory for purity and identity before release. A batch-specific Certificate of Analysis (COA) is available for each lot.
Purity
99.2%
Lab
Janoshik Analytical Laboratory
Batch
RETATR-2025-001
Test Date
2025-04-08
Orders placed before our daily cutoff ship the same business day. Free shipping on orders over $150, with tracking emailed as soon as your order leaves our facility.
Shipment protection covers your order against loss or damage in transit — if a protected order is lost or arrives damaged, our support team will arrange a replacement or resolution.
For in-vitro research and laboratory use only. This product is not a drug, supplement, food, or cosmetic, and has not been evaluated by the FDA.
Use is restricted to qualified researchers and laboratories operating within all applicable institutional, legal, and ethical guidelines. By purchasing, you confirm you are acquiring this product solely for lawful research purposes.
Retatrutide activates three receptors — GLP-1, GIP, and glucagon — in a single molecule, while tirzepatide activates only GIP and GLP-1, and semaglutide activates only GLP-1. The addition of glucagon receptor agonism introduces energy expenditure and hepatic fat oxidation mechanisms that are absent from dual agonists, which is believed to explain the superior weight reduction observed in Phase 2 clinical data (up to 24.2% at 48 weeks).
Retatrutide (LY3437943) completed Phase 2 clinical trials with results published in the New England Journal of Medicine in 2023, and Phase 3 trials are ongoing. It is being developed by Eli Lilly. This Pepcell product is a research-grade compound and is not the investigational drug used in those trials.
Reconstitute lyophilized retatrutide with bacteriostatic water, injecting slowly along the vial wall to avoid disrupting the peptide structure. The C20 fatty diacid acylation provides good solution stability. Do not shake. After reconstitution, store at 2-8°C and use within 30 days.
Each retatrutide batch undergoes independent third-party analysis at Janoshik Analytical Laboratory, including HPLC purity testing and mass spectrometry identity confirmation. Current batches test at 99.2% purity with batch-specific Certificates of Analysis available for every lot.
Retatrutide is sold exclusively for in-vitro research and laboratory investigation. It is not an FDA-approved drug — retatrutide remains in Phase 3 clinical trials and has not been approved for any therapeutic use. This research-grade compound is not intended for human consumption or self-administration.
